Drug General Information
Drug ID
D06XVF
Former ID
DCL001106
Drug Name
CBT-1
Indication Non-small cell lung cancer [ICD10:C33-C34] Phase 3 [521968]
Company
National Institutes of Health Clinical Center (CC)
Target and Pathway
Target(s) Multidrug resistance protein 1 Target Info Modulator
KEGG Pathway ABC transporters
Bile secretion
MicroRNAs in cancer
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database HIF-1-alpha transcription factor network
Reactome ABC-family proteins mediated transport
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity
Abacavir transport and metabolism
Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation
Integrated Pancreatic Cancer Pathway
Allograft Rejection
Drug Induction of Bile Acid Pathway
Codeine and Morphine Metabolism
References
Ref 521968ClinicalTrials.gov (NCT00437749) A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.